Tesamorelin
Growth Hormone Releasing Hormone Analogue
The targeted solution for reducing stubborn visceral fat.
Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH). It is specifically engineered to stimulate the pituitary gland to produce and release the body's own growth hormone. It is most recognized for its FDA-approved application in reducing excess visceral abdominal fat in HIV-infected patients with lipodystrophy.
Key Benefits
Mechanism of Action
Tesamorelin binds to and stimulates GHRH receptors on somatotroph cells in the anterior pituitary gland. This action triggers the synthesis and pulsatile release of endogenous growth hormone (GH). The subsequent increase in circulating GH leads to higher levels of Insulin-like Growth Factor 1 (IGF-1) from the liver, which mediates many of its metabolic effects, including enhanced lipolysis (fat breakdown).
Dosing Guidelines
Typical Dose
1-2 mg
Frequency
1x daily
Duration
12-26 weeks
Note: Administer subcutaneously in the evening before bed to mimic the body's natural GH pulse. It is best to inject on an empty stomach, at least 2 hours after the last meal.
Research & Studies
A comprehensive overview of Tesamorelin's mechanism, benefits, dosing, and research for visceral fat reduction.
Read Full ResearchPivotal clinical trials demonstrating Tesamorelin's efficacy and safety for treating lipodystrophy.
Read Full ResearchResearch exploring the potential neurocognitive benefits of GHRH analogues like Tesamorelin in aging populations.
Read Full ResearchPotential Side Effects
Reported side effects may include:
- • Injection site reactions (redness, itching, pain) - common
- • Arthralgia (joint pain) - common
- • Peripheral edema (mild fluid retention) - less common
- • Myalgia (muscle aches) - less common
- • Numbness or tingling in extremities (paresthesia)
- • Requires monitoring of IGF-1 levels on long cycles
This information is for research purposes only. Always consult with a healthcare professional.
Popular Stacking Options
Tesamorelin + Ipamorelin
Ipamorelin is a GHRP that works synergistically with Tesamorelin (a GHRH) to create a powerful, pulsatile release of growth hormone from the pituitary, amplifying fat loss and recovery benefits.
Shop this stackTesamorelin + AOD-9604
Combines Tesamorelin's GH-mediated lipolysis with AOD-9604's direct fat-burning mechanism, creating a focused stack for accelerated fat loss without significant systemic effects.
Shop this stackFrequently Asked Questions
How is Tesamorelin different from CJC-1295?
Tesamorelin is a GHRH analogue with a shorter half-life, promoting a more natural, pulsatile GH release that mimics the body's rhythm. CJC-1295 with DAC provides a constant, sustained elevation of GH levels, which can lead to receptor desensitization over time. Tesamorelin's action is considered more biomimetic and targeted.
Is Tesamorelin only for HIV patients?
While its FDA approval is for HIV-associated lipodystrophy, researchers are actively studying it for general visceral fat reduction, improved body composition, and cognitive benefits in non-HIV populations. Its targeted effect on visceral fat makes it a subject of interest for broader metabolic health applications.
Will Tesamorelin cause 'GH gut'?
'GH gut,' or visceral organ growth, is a risk associated with very high, long-term abuse of exogenous human growth hormone (HGH). Because Tesamorelin stimulates the body's own pulsatile release of GH, it is far less likely to cause this side effect, especially when used within recommended research protocols.
How long does it take to see results from Tesamorelin?
Significant reductions in visceral fat are typically measurable via imaging after about 12-26 weeks of consistent use. Subjective effects like improved energy or sleep quality might be noticed sooner, but the primary body composition changes require a longer duration protocol.
Ready to Purchase Tesamorelin?
Get pharmaceutical-grade Tesamorelin from Peptide Palace with 99%+ purity, third-party lab testing, and same-day dispatch.
Buy Tesamorelin Now